{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:31:37Z","timestamp":1792157497407,"version":"4.4.0"},"reference-count":84,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,18]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) is primarily a disease of older patients. Until recently, geriatric aspects in the context of MM have been poorly investigated. Treatment outcomes for geriatric patients with MM are often compromised by comorbidities and an enhanced susceptibility to adverse events from therapy. Assessment of patient frailty has become more frequent and will be useful in the context of significant and continuous advances in therapy. The recent emergence of immunotherapy with CD38 monoclonal antibodies and upcoming immunooncology drugs, such as bispecific antibodies, will lead to additional therapeutic progress. The applicability of these new molecules to older and frail patients is a key clinical question. Here, we present 2 patient cases derived from clinical practice. We review current frailty scores and standards of care for older, newly diagnosed patients with MM, including frail subgroups, and discuss ways to tailor treatment, as well as treatment perspectives in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2022017635","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T19:04:45Z","timestamp":1674587085000},"page":"224-232","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["How I treat multiple myeloma in geriatric patients"],"prefix":"10.1182","volume":"143","author":[{"given":"Thierry","family":"Facon","sequence":"first","affiliation":[{"name":"1Department of Hematology, University of Lille, Centre Hospitalier Universitaire Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"2Department of Hematology, University of Poitiers, Centre Hospitalier Universitaire Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University of Lille, Centre Hospitalier Universitaire Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2024011816212464900_bib1","unstructured":"Howlader\n              N\n            , NooneAM, KrapchoM, . SEER Cancer Statistics Review, 1975-2018. https:\/\/seer.cancer.gov\/csr\/1975_2018\/."},{"issue":"24","key":"2024011816212464900_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","article-title":"Multiple myeloma in the older adult: better prospects, more challenges","volume":"32","author":"Wildes","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9868","key":"2024011816212464900_bib3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"2024011816212464900_bib4","first-page":"423","article-title":"Multiple myeloma in the very elderly patient: challenges and solutions","volume":"11","author":"Willan","year":"2016","journal-title":"Clin Interv Aging"},{"issue":"13","key":"2024011816212464900_bib5","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2024011816212464900_bib6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0950-3536(05)80259-8","article-title":"The role of chemotherapy in the treatment of multiple myeloma","volume":"8","author":"Bergsagel","year":"1995","journal-title":"Baillieres Clin Haematol"},{"issue":"2","key":"2024011816212464900_bib7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"issue":"suppl","key":"2024011816212464900_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/01.HS9.0000846692.99498.08","article-title":"EMMY cohort: management of newly diagnosed or relapsed\/ refractory multiple myeloma in patients aged of 80 years and over [poster]","volume":"6","author":"Macro","year":"2022","journal-title":"HemaSphere"},{"key":"2024011816212464900_bib9","doi-asserted-by":"crossref","first-page":"201202","DOI":"10.1097\/01.HS9.0000844092.71570.04","article-title":"Health-related quality of life in transplant-ineligible real-life multiple myeloma patients treated with bortezomib-melphalan-prednisone (VMP) vs. lenalidomide-dexamethasone (Rd)","volume":"6","author":"D\u2019Agostino","year":"2022","journal-title":"HemaSphere"},{"key":"2024011816212464900_bib10","unstructured":"European Medicines Agency\n          . Points to consider on frailty: evaluation instruments for baseline characterisation of clinical trial populations. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/12\/WC500199243.pdf."},{"issue":"3","key":"2024011816212464900_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10198-010-0218-6","article-title":"Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma","volume":"12","author":"Muhlbacher","year":"2011","journal-title":"Eur J Health Econ"},{"issue":"6","key":"2024011816212464900_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"2024011816212464900_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024011816212464900_bib14","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-020-0713-4","article-title":"Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities","volume":"34","author":"Stege","year":"2020","journal-title":"Leukemia"},{"key":"2024011816212464900_bib15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/1471-2407-14-496","article-title":"Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life","volume":"14","author":"Osborne","year":"2014","journal-title":"BMC Cancer"},{"issue":"3","key":"2024011816212464900_bib16","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"2024011816212464900_bib17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits","volume":"62","author":"Rockwood","year":"2007","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"2024011816212464900_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1634\/theoncologist.2015-0326","article-title":"Optimizing the G8 screening tool for older patients with cancer: diagnostic performance and validation of a six-item version","volume":"21","author":"Martinez-Tapia","year":"2016","journal-title":"Oncologist"},{"issue":"9","key":"2024011816212464900_bib19","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2024011816212464900_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jgo.2019.07.004","article-title":"A\u00a0comparison of three different approaches to defining frailty in older patients with multiple myeloma","volume":"11","author":"Isaacs","year":"2020","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"9","key":"2024011816212464900_bib21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"2024011816212464900_bib22","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A\u00a0concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2024011816212464900_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"2024011816212464900_bib24","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2024011816212464900_bib25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A\u00a0simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2024011816212464900_bib26","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41375-021-01247-9","article-title":"External validation of the FIRST trial's simplified frailty score in a population-based cohort","volume":"35","author":"Mian","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2024011816212464900_bib27","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.3390\/cancers13123053","article-title":"Contemporary analysis of electronic frailty measurement in older adults with multiple myeloma treated in the national US Veterans Affairs Healthcare System","volume":"13","author":"DuMontier","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024011816212464900_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-019-00545-w","article-title":"Assessment of muscle function and physical performance in daily clinical practice: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)","volume":"105","author":"Beaudart","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2024011816212464900_bib29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"2024011816212464900_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/CIA.S168687","article-title":"Current and emerging biomarkers of frailty in the elderly","volume":"14","author":"Saedi","year":"2019","journal-title":"Clin Interv Aging"},{"issue":"3","key":"2024011816212464900_bib31","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A\u00a0clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"key":"2024011816212464900_bib32","doi-asserted-by":"crossref","first-page":"110858","DOI":"10.1016\/j.exger.2020.110858","article-title":"Inflammatory biomarkers of frailty","volume":"133","author":"Vatic","year":"2020","journal-title":"Exp Gerontol"},{"key":"2024011816212464900_bib33","doi-asserted-by":"crossref","first-page":"111014","DOI":"10.1016\/j.exger.2020.111014","article-title":"Circulating biomarkers characterizing physical frailty: CRP, hemoglobin, albumin, 25OHD and free testosterone as best biomarkers. Results of a meta-analysis","volume":"139","author":"Mailliez","year":"2020","journal-title":"Exp Gerontol"},{"issue":"3","key":"2024011816212464900_bib34","doi-asserted-by":"crossref","first-page":"e13314","DOI":"10.1111\/acel.13314","article-title":"Senescent cells and the incidence of age-related diseases","volume":"20","author":"Katzir","year":"2021","journal-title":"Aging Cell"},{"issue":"22","key":"2024011816212464900_bib35","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024011816212464900_bib36","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"issue":"9594","key":"2024011816212464900_bib37","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"2024011816212464900_bib38","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2024011816212464900_bib39","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2024011816212464900_bib40","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024011816212464900_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"10068","key":"2024011816212464900_bib42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"2024011816212464900_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"2024011816212464900_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A\u00a0phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"2024011816212464900_bib45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024011816212464900_bib46","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024011816212464900_bib47","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024011816212464900_bib48","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"2024011816212464900_bib49","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2024011816212464900_bib50","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"22","key":"2024011816212464900_bib51","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2024011816212464900_bib52","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024011816212464900_bib53","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"HemaSphere"},{"issue":"5","key":"2024011816212464900_bib54","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"2024011816212464900_bib55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024011816212464900_bib57","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"issue":"10218","key":"2024011816212464900_bib56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"2024011816212464900_bib58","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2024011816212464900_bib59","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2018-99-117003","article-title":"Longer term follow up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"132","author":"Durie","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024011816212464900_bib60","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1182\/blood-2019-128000","article-title":"Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in transplant-ineligible multiple myeloma","volume":"134","author":"O'Donnell","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2024011816212464900_bib61","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1182\/blood-2021-149480","article-title":"RD vs. VRD: what is the first-line, real-life management of multiple myeloma patients ineligible for stem cell auto transplantation in the Emmy cohort?","volume":"138","author":"Decaux","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024011816212464900_bib62","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/ajh.25963","article-title":"Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma","volume":"95","author":"Durie","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"2024011816212464900_bib63","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024011816212464900_bib64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2024011816212464900_bib65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134322","article-title":"Efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in elderly patients with relapsed and refractory multiple myeloma: KarMMa subgroup analysis","volume":"136","author":"Berdeja","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2024011816212464900_bib66","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1182\/bloodadvances.2020001965","article-title":"Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and\/or refractory multiple myeloma","volume":"4","author":"Facon","year":"2020","journal-title":"Blood Adv"},{"issue":"25","key":"2024011816212464900_bib67","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 Study","volume":"39","author":"Stege","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024011816212464900_bib68","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2022-159933","article-title":"A\u00a0dexamethasone sparing-regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: efficacy and safety analysis of the phase 3 IFM2017-03 trial","volume":"140","author":"Manier","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024011816212464900_bib69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2021-146650","article-title":"Fitness, a UK Myeloma Research Alliance (UK-MRA) frailty-adjusted therapy study, supports the feasibility of recruiting frail newly diagnosed myeloma patients to large clinical trials","volume":"138","author":"Cook","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2024011816212464900_bib70","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"2024011816212464900_bib72","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024011816212464900_bib73","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"issue":"3","key":"2024011816212464900_bib74","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024011816212464900_bib75","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","article-title":"Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy","volume":"107","author":"Facon","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2024011816212464900_bib76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"22","key":"2024011816212464900_bib77","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2024011816212464900_bib79","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2024011816212464900_bib78","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"2024011816212464900_bib80","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A\u00a0predictive model for risk of early grade \u2265 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"2024011816212464900_bib81","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024011816212464900_bib82","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2024011816212464900_bib83","doi-asserted-by":"crossref","first-page":"e934","DOI":"10.1016\/S2352-3026(21)00278-7","article-title":"COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network","volume":"8","author":"Ludwig","year":"2021","journal-title":"Lancet Haematol"},{"key":"2024011816212464900_bib84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13690-015-0095-7","article-title":"Factors associated with excessive polypharmacy in older people","volume":"73","author":"Walckiers","year":"2015","journal-title":"Arch Public Health"},{"issue":"9","key":"2024011816212464900_bib85","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","article-title":"Survival and years of life lost in different age cohorts of patients with multiple myeloma","volume":"28","author":"Ludwig","year":"2010","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/3\/224\/2181699\/blood_bld-2022-017635-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/3\/224\/2181699\/blood_bld-2022-017635-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T16:22:01Z","timestamp":1705594921000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/3\/224\/494221\/How-I-treat-multiple-myeloma-in-geriatric-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017635","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}